Researchers at the University of Sheffield have received new funding to investigate if radium-223 (Ra-223), currently used to treat bone metastases in prostate cancer, might also help in bone spread ...

May 21, 2012 (Atlanta, Georgia) — In patients with bone metastases and castration-resistant prostate cancer (CRPC), radium-223 chloride (Ra-223) significantly prolonged overall survival and delayed ...

Scientists need a better understanding of the chemistry of radium to be able to target the isotope radium-223 (Ra-223) to cancer cells. Once delivered, Ra-223 can destroy those cells with alpha ...

Researchers are testing new combinations of drugs to treat breast cancer that’s spread to the bone, thanks to funding from Breast Cancer Now. The charity has awarded £142,714 to Professor Penelope ...

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases. Final data from the phase 3 EORTC ...

Neal Shore, MD, is the National Urology Research Director for 21 st Century Oncology in Myrtle Beach, SC. He has been extensively involved in clinical trials of medications for treating prostate ...

Men with castration-resistant prostate cancer (CRPC) and asymptomatic or mildly symptomatic bone metastases lived significantly longer when they received enzalutamide (Xtandi) plus radium-223 (Ra-223, ...

An new editorial offers an explanation why radium-223 used in combination with prednisone and abiraterone did not lower the risk of symptomatic skeletal events in men with mCRPC. Bone loss resulting ...

RNA-Based Homologous Recombination Deficiency Signature Detects Homologous Recombination Deficiency-RNA+ Patients With and Without Homologous Recombination Repair Gene Pathogenic Alterations in Men ...

Final results for the key secondary endpoint of overall survival (OS) from the PEACE-3 trial will be presented by the European Organization for Research and Treatment of Cancer (EORTC) coalition as an ...

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared ...